A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Trial Profile

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs MOR 208 (Primary) ; Lenalidomide
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms L-MIND
  • Sponsors MorphoSys
  • Most Recent Events

    • 25 Jun 2017 Results (n=31, data cut off 3 january 2017) presented at the 22nd Congress of the European Haematology Association
    • 06 Jun 2017 Results (n=30 as of 3 Jan 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 03 Aug 2016 According to MorphoSys media release, the company expects to present first efficacy data of the trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top